---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-000113"
form_type: "8-K"
ticker: "ABUS"
cik: "0001447028"
company_name: "Arbutus Biopharma Corp"
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:11:03.991767+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Arbutus provides 2024 outlook: $132M cash, reduced burn, multiple Phase 2a readouts expected in 1H 2024

## Summary
- Cash, equivalents and investments ~$132M at Dec 31, 2023; net burn expected $63-67M in 2024 vs ~$85M in 2023.
- Cash runway extends into Q1 2026.
- End-of-treatment data from imdusiran Phase 2a trials AB-729-201 and AB-729-202 expected 1H 2024.
- Third Phase 2a imdusiran trial (AB-729-203, with durvalumab) to begin in 1H 2024; AB-101 Phase 1a/1b data also expected 1H 2024.
- Moderna LNP claim construction hearing set Feb 8, 2024; trial expected 1H 2025. Pfizer/BioNTech lawsuit ongoing.

## SEC filing metadata
- accession: 0001171843-24-000113
- form_type: 8-K
- ticker: ABUS
- cik: 0001447028
- company_name: Arbutus Biopharma Corp
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447028/000117184324000113/0001171843-24-000113-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447028/000117184324000113/f8k_010624.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-000113
- JSON: https://secwatch.observer/filing/0001171843-24-000113.json
- Plain text: https://secwatch.observer/filing/0001171843-24-000113.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.